tailieunhanh - Targeting CD33 for acute myeloid leukemia therapy

The aim of this study was to analyze the level of CD33 expression in patients with newly diagnosed AML and determine its correlation with clinical characteristics. Methods: Samples were collected for analysis from AML patients at diagnosis. We evaluated the level of CD33 expression by flow cytometry analysis of bone marrow. | Liu et al. BMC Cancer 2022 22 24 https s12885-021-09116-5 RESEARCH ARTICLE Open Access Targeting CD33 for acute myeloid leukemia therapy Jingjing Liu Jiayin Tong and Haiping Yang Abstract Background The aim of this study was to analyze the level of CD33 expression in patients with newly diagnosed AML and determine its correlation with clinical characteristics. Methods Samples were collected for analysis from AML patients at diagnosis. We evaluated the level of CD33 expression by flow cytometry analysis of bone marrow. Chi-square or t- tests were used to assess the association between the high and low CD33 expression groups. Survival curves were generated by the Kaplan-Meier and Cox regression model method. Results In this study we evaluated the level of CD33 expression in de novo patients diagnosed from November 2013 until January 2019. The mean value of was used as the cutoff for the two groups. Statistical analysis revealed that 53 of the 86 AML patients were above the mean. Although there was no statistical significance between CD33 expression level and gene mutation FLT3 mutation P and NPM1 mutation P were more likely to be seen in the high CD33 group. The overall survival OS was worse in the high CD33 group m vs. m x2 P Liu et al. BMC Cancer 2022 22 24 Page 2 of 7 in hematopoietic stem and progenitor cells increasing patients were diagnosed evaluated and treated according off-target toxicity and killing hematopoietic stem and to National Comprehensive Cancer Network NCCN progenitor cells in immunotherapy 3 6 7 . guidelines 13 . All patients records were evaluated Most efforts of developing monoclonal antibodies or retrospectively for the level of CD33 expression in de antibody-drug conjugates ADCs for AML have focused novo AML patients. Patients were grouped according to on targeting CD33 cluster of differentiation antigen expression levels above and under the mean that is into 33 . Leukemic blasts and .